Inherited retinal degenerations are a diverse group of genetic disorders that result in progressive vision loss. Advances in ...

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study designFDA indicates Opus Genetics may submit a BLA based on ...

Researchers at the University of Oklahoma are advancing the fight against inherited retinal diseases (IRDs) with new genetic research that aims to improve diagnoses and lay the groundwork for future ...

Inherited retinal degenerations (IRDs) are a group of genetic disorders that lead to progressive vision loss as the light-sensing cells of the eye—the photoreceptors—die due to mutations in genes ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

A new study challenges what's long been assumed about genetic variants thought to always cause inherited blindness. Investigators from Mass General Brigham used large public biobanks to determine that ...

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have ...

Opus Genetics, Inc., a clinical-stage biotechnology company focusing on gene therapies for inherited retinal diseases, announced upcoming presentations at various scientific conferences in May 2025.

Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.